Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633956 · ClinicalTrials.gov registry record · Phase 2
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
A Phase 2 study, sponsored by Intercept Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT02633956 is a Phase 2 study that has completed, run by Intercept Pharmaceuticals. The registered enrollment target is 84 participants.
The verdict
NCT02633956, a Phase 2 study, has completed, sponsored by Intercept Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on lipoprotein metabolism in subjects with nonalcoholic steatohepatitis (NASH) with fibrosis stage 1 to 4, but no evidence of hepatic decompensation.
Interventions
- DRUG Placebo
- DRUG Atorvastatin
- DRUG Obeticholic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-12-04 |
| Est. Completion | 2018-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633956
The ClinicalTrials.gov registry entry for NCT02633956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercept Pharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02633956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02633956 about?
NCT02633956 is a clinical study titled "Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)". This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on lipoprotein metabolism in subjects with nonalcoholic steatohepatitis (N...
What is the current status of trial NCT02633956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2015-12-04. Estimated completion is 2018-03-12.
What interventions are being tested in trial NCT02633956?
The interventions under investigation include: Placebo (DRUG), Atorvastatin (DRUG), Obeticholic Acid (DRUG).
Who is sponsoring clinical trial NCT02633956?
This trial is sponsored by Intercept Pharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.